The Role of Chemotherapy in Triple Negative Breast Cancer

Almuradova Dm

doi:10.31031/ooij.2018.02.000533

Abstract

The Role of Chemotherapy in Triple Negative Breast Cancer

Highlights

Triple-negative breast cancers have a relapse pattern that is very different from hormone-positive breast cancers: the risk of relapse is much higher for the first 3-5 years but drops sharply and substantially below after that hormone-positive breast cancers
The multiple logistic regression model showed that TNBC subtype, high grade, and smaller tumor size were associated with higher rates in the breast, but when considering the breast and nodes, the addition of carboplatin was significantly related to a better result in hormone receptor-positive tumors only
Even if conventional gemcitabine demonstrated to be more active in endocrine receptor-negative tumors and are indicated in the first-line treatment of TNBC, it should be considered that they are commonly used in adjuvant therapy and cannot be challenged in case of short disease-free interval (

Summary

Introduction

Triple-negative breast cancers have a relapse pattern that is very different from hormone-positive breast cancers: the risk of relapse is much higher for the first 3-5 years but drops sharply and substantially below after that hormone-positive breast cancers. According to the Ministry of Health of Uzbekistan, the most common cancer in the country is breast cancer This type of cancer is diagnosed in 9.1 cases per 100 thousand of the population. The hereditary factor is important in the development of breast cancer in women, it is on the maternal line. It is transmitted in 45-75% of cases, if there are mutations of BRSA 1-2 genes. Purpose of the study is to evaluate the effectiveness of various chemotherapy regimens for neoadjuvant, adjuvant and palliative polychemotherapy (metastatic) in patients triple negative breast cancer with improved long-term treatment outcomes.

Materials and Methods of Research

Result

Findings

Conclusion